PI3K-IN-1 uxadoline Smiles: CN1CC(=O)N2[C@H]([C@H](C)N(CC3=CC=CC4=CC=CN=C34)C(=O)[C@@H]2CC2C=CC(=CC=2)OP(O)(O)=O)N1C(=O)NCC1C=CC=CC=1

Smiles: CN1CC(=O)N2[C@H]([C@H](C)N(CC3=CC=CC4=CC=CN=C34)C(=O)[C@@H]2CC2C=CC(=CC=2)OP(O)(O)=O)N1C(=O)NCC1C=CC=CC=1

InChiKey: JGPMMRGNQUBGND-UHFFFAOYSA-N

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R

Pico-Salax

CAS Number: 101831-37-2

PI3K-IN-1 uxadoline Smiles: CN1CC(=O)N2[C@H]([C@H](C)N(CC3=CC=CC4=CC=CN=C34)C(=O)[C@@H]2CC2C=CC(=CC=2)OP(O)(O)=O)N1C(=O)NCC1C=CC=CC=1Voxtalisib, also known as XL 765 and SAR245409, is a PI3K mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K mTOR signaling pathway, with potential antineoplastic activity. PI3K mTOR dual kinase inhibitor XL765 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in